SAFETY AND ACTIVITY OF THE HIGHLY SPECIFIC BTK INHIBITOR, BGB‐3111 PLUS OBINUTUZUMAB IN PATIENTS (PTS) WITH FOLLICULAR LYMPHOMA (FL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). (June 2017) - Tam, C.S.; Quach, H.; Nicol, A.; Badoux, X.; Rose, H.; Prince, H.; Leahy, M.F.; Eek, R.; Wickham, N.; Patil, S.; Huang, J.; Zhang, X.; et al.